-
This review focusses on current knowledge of the roles of IRF-1 and IRF-2 in human cancer, with particular attention paid to the impact of IRF-1 inactivation.
-
Data suggest that MIR1290 expression is remarkably upregulated in non-small-cell lung carcinoma tissues compared to adjacent normal lung tissues; IRF2 appears to be a direct target of MIR1290. (MIR1290 = microRNA-1290; IRF2 = interferon regulatory factor-2)
-
These finding suggests that miR-302b inhibits key transcription factors and cytokines by targeting ERBB4, IRF2 and CXCR4, implicating its role in the inhibition of CRI in EC.
-
Our study primarily suggests IRF-2 as a potential prognostic biomarker in colorectal cancer
-
The effects of IRF2 suppresses non-small cell lung cancer by promoting cell apoptosis, inhibiting cell proliferation and migration ability.
-
In a genome wide are study to identify acute kidney injury risk in critically ill patients, the locus on chromosome 4, located 150 kb upstream of IRF2 was identified to regulate immunity pathways related to kidney disease risk gene APOL1. Disruption of IRF-2 has been found to up-regulate the inflammatory response to infection.
-
Study shows that IRF2 knockdown inhibits growth, colony formation of OCI/AML-2, OCI/AML-3, and THP-1 cells. In addition, IRF2 knockdown induces apoptosis of acute myeloid leukemia (AML) cells by regulating apoptotic effectors. Further mechanism analysis shows that INPP4B contributes to the effects of IRF2 on apoptosis and growth of AML cells. Thus, IRF2 serves as an important regulator in AML by targeting INPP4B.
-
miR-450 targets IRF2 and thus supresses lung cancer cell proliferation and invasion.
-
It might play as a tumor suppressor by regulating P53 signaling in gastric cancer.
-
the association of IRF2 with susceptibility to systemic lupus erythematosus
-
IRF2genes were not associated with pancreatitis. 4 variants were found: c.123G>A (novel), c.651C>T, c.744G>A, and c.638C>T, p.P213L.
-
Data suggest that interferon regulatory factors 1 and 2 (IRF1 and IRF2) may serve as potential targets of therapy.
-
miR-221 directly inhibits the expression of SOCS3 and IRF2.
-
KGF could up-regulate IL-7 expression through the STAT1/IRF-1, IRF-2 signaling pathway, which is a new insight in potential effects of KGF on the intestinal mucosal immune system.
-
IFN regulatory factor 2 (Irf2) has a regulatory role in trypsinogen5 gene transcription, which is resistant to a major endogenous trypsin inhibitor, Spink3
-
IRF2 overexpression protects against I/R injury by decreasing IRF1-dependent injury and may represent a novel therapeutic strategy.
-
The results suggested that distinct markers in IRF2 may be associated with atopic dermatitis and eczema herpeticum (which may depend upon ethnic ancestry) and genetic variants in IRF2 may contribute to an abnormal immune response to herpes simplex virus.
-
these results suggest that IRF-2 plays an important role in the tumorigenesis of pancreatic cancer and down-regulation of IRF-2 would be a new treatment target for pancreatic cancer.
-
IRF-2 activates the HPV-16 P97 promoter in vivo.
-
IRF-2 activates RIG-I promoter through ISRE-like site as well as IRF-1 and IFN-alpha stimulation.